While we are recovering and taking control of the virus among us, struggling with an economic downturn, and trying to give voice to solve social injustices, progress is still being made in the world of neurotechnology. These developments could have or will have an impact on people living with neurological conditions. Let’s take a look at what made headlines over the month of May 2020.
These headlines highlight technical advancements, changes in access and expanding applications of current technologies.
Setpoint Medical received approval from the FDA to begin their pivotal clinical trial testing their implanted vagus nerve stimulation system to treat Rheumatoid Arthritis.
Helius Medical received Breakthrough Device Designation from the FDA to use their PoNS device for the treatment of gait issues for people living with multiple sclerosis.
Telehealth has quickly become accessible to many more people. ReWalk is exploring how they can incorporate telehealth technology into their exoskeleton technology. (as reported in the Worcester Business Journal). The company also announced expanded insurance coverage of Germany’s DGUV for those living with spinal cord injury.
Pear Therapeutics is helping out during the COVID-19 pandemic. This is all about people living with with schizophrenia gaining access to Pear-004 for use in combination with atypical anti-psychotic medications.
MYOLYN received patent approval for automating the setup and optimization of FES Cycling parameters. This latest technology will allow those with lower limb weakness or paralysis to access technology typically found in rehabilitation centers and neurogyms.
Exciting news for those living with obstructive sleep apnea. Inspire Medical Systems announced expanded Medicare coverage decisions in specific states by June.
Brain interface scientists have new findings of how we record memory during sleep. The study was conducted by scientists at Braingate.
For those living with chronic pain in Europe, Nevro’s Senza Omnia spinal cord stimulator received CE Mark approval. The device includes a new user interface and options for physical adjusted parameters.
For those with hearing impairments, there are new findings evaluating who is best fit for a cochlear implant to achieve speech perception outcomes. The article is a meta-analysis published in the Journal of the American Medical Association.
Also reported this month, Cochlear received FDA approval lowering the age for implant to 9-mo of age. This expands treatment for U.S. children with hearing impairments as candidates for cochlear implants.
Axonics Modulation Technologies, Inc. recently published 1-yr results from the ARTISAN study demonstrating a 93% satisfaction rate among people using their r-SNM device for urinary and bowel dysfunctions.
Finally, we are honored to be among those selected for the NYC Neuromodulation 2020 awards for service to the community! See the other winners here.